The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
A Controlled Trial Comparing Vidarabine with Acyclovir in Neonatal Herpes Simplex Virus Infection
Open accessAbstract
BACKGROUND: Despite the use of vidarabine, herpes simplex virus (HSV) infection in neonates continues to be a disease of high morbidity and mortality. We undertook a controlled trial comparing vidarabine with acyclovir for the treatment of neonatal HSV infection. METHODS: Babies less than one month of age with virologically confirmed HSV infection were randomly and blindly assigned to receive either intravenous vidarabine (30 mg per kilogram of body weight per day; n = 95) or acyclovir (30 mg per kilogram per day; n = 107) for 10 days. Actuarial rates of mortality and morbidity among the survivors after one year were compared overall and according to the extent of the disease at entry into the study (infection confined to the skin, eyes, or mouth; encephalitis; or disseminated disease). RESULTS: After adjustment for differences between groups in the extent of disease, there was no difference between vidarabine and acyclovir in either morbidity (P = 0.83) or mortality (P = 0.27). None of the 85 babies with disease confined to the skin, eyes, or mouth died. Of the 31 babies in this group who were treated with vidarabine and followed for a year, 88 percent (22 of 25) were judged to be developing normally after one year, as compared with 98 percent (45 of 46) of the 54 treated with acyclovir (95 percent confidence interval for the difference, -4 to 24). For the 71 babies with encephalitis, mortality was 14 percent with vidarabine (5 of 36) and with acyclovir (5 of 35); of the survivors, 43 percent (13 of 30) and 29 percent (8 of 28), respectively, were developing normally after one year (95 percent confidence interval for the difference, -11 to 39). For the 46 babies with disseminated disease, mortality was 50 percent (14 of 28) with vidarabine and 61 percent (11 of 18) with acyclovir (95 percent confidence interval for the difference, -20 to 40); of the survivors, 58 percent (7 of 12) and 60 percent (3 of 5), respectively, were judged to be developing normally after one year (95 percent confidence interval for the difference, -40 to 50). Both medications were without serious toxic effects. CONCLUSIONS: In this multicenter, randomized, blinded study there were no differences in outcome between vidarabine and acyclovir in the treatment of neonatal HSV infection. The study lacked statistical power to determine whether there were sizable differences within the subgroups of those with localized HSV, encephalitis, or disseminated disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine
Elion, G. B., Furman, P. A., Fyfe, J. A., Miranda, P. D., Beauchamp, L., & Schaeffer, H. J. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5716 · Cited by 1,591
Vidarabine versus Acyclovir Therapy in Herpes Simplex Encephalitis
Whitley, R. J., Alford, C. A., Hirsch, M. S., Schooley, R. T., Luby, J. P., Aoki, F. Y., Hanley, D., Nahmias, A. J., Soong, S.-J., & The NIAID Collaborative Antiviral Study Group* (1986) · New England Journal of Medicine · doi:10.1056/nejm198601163140303 · Cited by 896
Self-citationThe Natural History of Herpes Simplex Virus Infection of Mother and Newborn
Whitley, R. J., Nahmias, A. J., Visintine, A. M., Fleming, C. L., Alford, C. A., Yeager, A., Arvin, A., Haynes, R., Hilty, M., & Luby, J. (1980) · Pediatrics · doi:10.1542/peds.66.4.489 · Cited by 462
Self-citationPredictors of Morbidity and Mortality in Neonates with Herpes Simplex Virus Infections
Whitley, R., Arvin, A., Prober, C., Corey, L., Burchett, S., Plotkin, S., Starr, S., Jacobs, R., Powell, D., Nahmias, A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240704 · Cited by 410
Self-citationIntrauterine herpes simplex virus infections
Hutto, C., Arvin, A., Jacobs, R., Steele, R., Stagno, S., Lyrene, R., Willett, L., Powell, D., Andersen, R., Werthammer, J., et al. (1987) · The Journal of Pediatrics · doi:10.1016/s0022-3476(87)80298-6 · Cited by 370
Self-citationVidarabine Therapy of Neonatal Herpes Simplex Virus Infection
Whitley, R. J., Nahmias, A. J., Soong, S.-J., Galasso, G. G., Fleming, C. L., Alford, C. A., Connor, J., Bryson, Y., & Linnemann, C. (1980) · Pediatrics · doi:10.1542/peds.66.4.495 · Cited by 358
Self-citationChanging Presentation of Herpes Simplex Virus Infection in Neonates
Whitley, R. J., Corey, L., Arvin, A., Mintz, E., Lakeman, F. D., Sumaya, C. V., Wright, P. F., Dunkle, L. M., Steele, R. W., Soong, S.-J., et al. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/158.1.109 · Cited by 335
Self-citationDrugs Five Years Later: Acyclovir
DORSKY, D. I., & CRUMPACKER, C. S. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-6-859 · Cited by 162
Neonatal Herpes Simplex Virus Infection: Follow-up Evaluation of Vidarabine Therapy
Whitley, R. J., Yeager, A. S., Kartus, P. L., Bryson, Y. J., Connor, J. D., Alford, C. A., Nahmias, A. J., & Soong, S. (1983) · PEDIATRICS · doi:10.1542/peds.72.6.778 · Cited by 136
Self-citationGutman, L. T., Wilfert, C. M., & Eppes, S. B. (1986) · The Journal of Infectious Diseases · doi:10.1093/infdis/154.3.415 · Cited by 82
Cited by
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Herpes simplex virus infections
Whitley, R. J., & Roizman, B. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04638-9 · Cited by 1,366
Self-citationWhitley, R. J., Kimberlin, D. W., & Roizman, B. (1998) · Clinical Infectious Diseases · doi:10.1086/514600 · Cited by 1,149
Self-citationSimonsen, K. A., Anderson-Berry, A. L., Delair, S. F., & Davies, H. D. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-13 · Cited by 984
Natural History of Neonatal Herpes Simplex Virus Infections in the Acyclovir Era
Kimberlin, D. W., Lin, C.-Y., Jacobs, R. F., Powell, D. A., Frenkel, L. M., Gruber, W. C., Rathore, M., Bradley, J. S., Diaz, P. S., Kumar, M., et al. (2001) · Pediatrics · doi:10.1542/peds.108.2.223 · Cited by 507
Self-citation
Metadata
- Authors
- Whitley, R., Arvin, A., Prober, C., Burchett, S., Corey, L., Powell, D., Plotkin, S., Starr, S., Alford, C., Connor, J., Jacobs, R., Nahmias, A., Soong, S.-J., & the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group*
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1991-02-14
- Volume
- 324
- Issue
- 7
- Pages
- 444-449
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2953732145
- Cited by
- 388
- References
- 13
- FWCI
- 20.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Controlled Trial Comparing Vidarabine with Acyclovir in Neonatal Herpes Simplex Virus Infection. https://app.cochat.ai/papers/10.1056/nejm199102143240703
- The paper
- Whitley, R., Arvin, A., Prober, C., Burchett, S., Corey, L., Powell, D., Plotkin, S., Starr, S., Alford, C., Connor, J., Jacobs, R., Nahmias, A., Soong, S.-J., & the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group*. (1991). A Controlled Trial Comparing Vidarabine with Acyclovir in Neonatal Herpes Simplex Virus Infection. New England Journal of Medicine. https://doi.org/10.1056/nejm199102143240703
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.